Search

Jon E. Angell

Examiner (ID: 10917, Phone: (571)272-0756 , Office: P/1674 )

Most Active Art Unit
1635
Art Unit(s)
1674, 1637, 1635
Total Applications
1421
Issued Applications
715
Pending Applications
203
Abandoned Applications
529

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16597923 [patent_doc_number] => 20210024454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => NOVEL COMPOUND AND PHARMACETICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC SYNDROME COMPRISING THEREOF [patent_app_type] => utility [patent_app_number] => 17/041960 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041960 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/041960
Compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising thereof Mar 25, 2019 Issued
Array ( [id] => 17334537 [patent_doc_number] => 20220000868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => NOVEL 4-CARBONYLAMINO-4-PHENYLPYRIMIDINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF [patent_app_type] => utility [patent_app_number] => 17/297198 [patent_app_country] => US [patent_app_date] => 2018-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17297198 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/297198
4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof Nov 25, 2018 Issued
Array ( [id] => 16718564 [patent_doc_number] => 20210085711 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => USE OF FERRIC CITRATE IN PREVENTION AND/OR TREATMENT OF IRON-DEFICIENCY ANEMIA IN HYPERMENORRHEA PATIENT AND/OR PATIENT SUFFERING FROM HYPERMENORRHEA-ASSOCIATED GYNECOLOGIC DISEASE [patent_app_type] => utility [patent_app_number] => 16/647994 [patent_app_country] => US [patent_app_date] => 2018-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647994 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/647994
USE OF FERRIC CITRATE IN PREVENTION AND/OR TREATMENT OF IRON-DEFICIENCY ANEMIA IN HYPERMENORRHEA PATIENT AND/OR PATIENT SUFFERING FROM HYPERMENORRHEA-ASSOCIATED GYNECOLOGIC DISEASE Sep 17, 2018 Abandoned
Array ( [id] => 17141630 [patent_doc_number] => 20210309642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => Process for Manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and Formulations Thereof [patent_app_type] => utility [patent_app_number] => 17/266075 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266075 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/266075
Process for manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy)phenyl)acrylamide, and formulations thereof Aug 8, 2018 Issued
Array ( [id] => 19331203 [patent_doc_number] => 20240245633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => ROR Gamma Agonists as Enhancers of Protective Immunity [patent_app_type] => utility [patent_app_number] => 15/768888 [patent_app_country] => US [patent_app_date] => 2016-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 203 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768888 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/768888
ROR Gamma Agonists as Enhancers of Protective Immunity Oct 31, 2016 Abandoned
Menu